Faron Pharmaceuticals Oy (LON:FARN)
47.00p
Spriggl Score: Poor— see the number + sub-scores with a free Spriggl account
Last 30 trading days
Spriggl AI Verdict
“Binary trial risk and severe dilution overshadow promising early data for this pre-revenue biotech.”
Sign up free to read the full investment thesis, bull case, bear case and what to watch.
About Faron Pharmaceuticals Oy
Faron Pharmaceuticals Oy operates as a clinical stage drug discovery and development company. The company's lead product candidate is Bexmarilimab, a novel anti-Clever-1 humanized antibody that targets a subpopulation of tumor-associated macrophages and converts the highly immuno…
- Sector:
- Healthcare
- Industry:
- Biotechnology
- Market Cap:
- £93.8M
Recent dividends
No recent dividends recorded.
Get the full Spriggl analysis — free
Sign up for a free Spriggl account to unlock the full Spriggl Score breakdown, screener, watchlist, and AI investment analysis on Faron Pharmaceuticals Oy and 1,600+ UK and US stocks.
Start free